Are you more inclined to use neoadjuvant endocrine therapy over neoadjuvant chemotherapy or upfront surgery for your ER+HER2- breast cancer patients during the COVID19 pandemic?

Topics: Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • UCLA • COVID-19

Personally, my practice is to guide patients directly to surgery or to do neoadjuvant chemotherapy rather than to do neoadjuvant endocrine therapy, but I can't guarantee medical services such as staging, OR time, or months of chemotherapy when the support staff are self-quarantining or staying home to care for their children because the schools and daycares are closed.

Answer from: Medical Oncologist at Academic Institution

For clinically low risk early stage node negative tumors that are strongly ER/PR+ HER2-, neoadjuvant endocrine therapy with follow up is reasonable during this phase of the pandemic. ASCO has released some guidance to help with these questions. Ultimately, we will need to work together to cons...

Comments

Medical Oncologist at Grand River Regional Cancer Centre
Does a clip need to be placed?

Medical Oncologist at H Lee Moffitt Cancer Center, University of South Florida
The PCR rate is low and there usually is still tum...

Related Questions